Supplementary Material for: Prevalence of Phototherapy in the Age of Biologics

<b><i>Background:</i></b> The prevalence of narrow-band ultraviolet B (NB-UVB) use in Europe for moderate and severe psoriasis is unknown, because national registries for psoriasis do not monitor this treatment. <b><i>Objectives:</i></b> To quantify the use of phototherapy, biologics or conventional treatments in psoriasis, in a setting where European Medicines Agency (EMA) eligibility criteria for biologics were strictly applied, and phototherapy was included among first-line treatments. <b><i>Methods:</i></b> We followed a cohort of 1,090 patients who were referred to the only centre entitled to prescribe biologics and phototherapy during a 5-year period. <b><i>Results:</i></b> The cumulative number of treatment cycles was: 1,047 with NB-UVB phototherapy, 650 with systemic treatments and 239 with biologics; 754 patients received at least 1 course of NB-UVB phototherapy, 422 at least 1 course with a systemic treatment and 137 with a biologic; 595 patients were treated only with phototherapy. <b><i>Conclusions:</i></b> Regular use of NB-UVB as first-line treatment for moderate and severe psoriasis and adherence to the EMA eligibility criteria for biologics led to a relatively restricted use of biologics.

**背景：** 由于欧洲各国的银屑病登记系统未对该治疗手段进行监测，目前尚不明确中重度银屑病患者在欧洲使用窄谱中波紫外线（NB-UVB）的比例。
**研究目的：** 在严格执行欧洲药品管理局（EMA）生物制剂准入标准、且将光疗（phototherapy）纳入一线治疗方案的场景下，量化银屑病患者光疗、生物制剂（biologics）及常规治疗的使用情况。
**研究方法：** 本研究对5年内转诊至唯一一家可开具生物制剂与光疗处方的医疗中心的1090例患者开展队列随访。
**研究结果：** 累计治疗周期数分别为：窄谱中波紫外线光疗1047个周期、系统治疗（systemic treatments）650个周期、生物制剂治疗239个周期；其中754例患者至少接受过1个周期的窄谱中波紫外线光疗，422例患者至少接受过1个周期的系统治疗，137例患者接受过生物制剂治疗；另有595例患者仅接受光疗。
**研究结论：** 将窄谱中波紫外线作为中重度银屑病的一线治疗方案，且严格遵循欧洲药品管理局（EMA）的生物制剂准入标准，可使生物制剂的使用相对受限。